Physician profile
William B Painter
NPI 1912015686
$1,920.04
in general payments reported to CMS, 2019-2025
23 companies · $399 in 2025
The $399 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $54.82 · 2021: $127 · 2022: $185 · 2023: $220 · 2024: $763 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,382.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $643.52 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $258.03 | 2019-2025 | Doc Band |
| Pfizer INC. | $246.30 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $118.52 | 2019-2024 | |
| Tris Pharma INC | $86.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.75 | 2020-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Alk-Abello, INC | $55.11 | 2025 | Neffy, Grastek, Odactra |
| Takeda Pharmaceuticals U.S.A., INC. | $53.83 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $40.54 | 2023 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $35.83 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $33.56 | 2019-2025 | |
| Corium, LLC | $30.77 | 2022-2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $30.42 | 2019-2020 | |
| Neurelis, INC. | $30.19 | 2022 | |
| Adlon Therapeutics L.P. | $26.05 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $24.39 | 2023 | |
| Glaxosmithkline, LLC. | $23.95 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $23.89 | 2024 | Crysvita |
| Ironwood Pharmaceuticals, INC | $19.20 | 2024 | |
| Cipher Pharmaceuticals US LLC | $16.40 | 2025 | Natroba, Spinosad |
| Jazz Pharmaceuticals INC. | $14.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.04 | 2019 | |
| Shire North American Group INC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Painter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.